2. Search Result
Search Result
Results for "

PI4KIII-beta-inhibitor-1

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Peptides

1

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125118
    GSK-A1
    2 Publications Verification

    		 PI4K HCV Infection
    GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research [1].
    GSK-A1
  • HY-15679
    PI4KIII beta inhibitor 3
    3 Publications Verification

    		 PI4K Cancer
    PI4KIII beta inhibitor 3 is a novel and high effective PI4KIIIβ inhibitor with IC50 of 5.7 nM.
    PI4KIII beta inhibitor 3
  • HY-12046
    PIK-93
    5+ Cited Publications

    		 PI4K PI3K Virus Protease Cancer
    PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM, and also inhibits PI3Kγ and PI3Kα with IC50 of 16 nM and 39 nM, respectively.
    PIK-93
  • HY-100198
    PI4KIIIbeta-IN-10
    Maximum Cited Publications
    15 Publications Verification

    		 PI4K PI3K Infection
    PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC50 of 3.6 nM.
    PI4KIIIbeta-IN-10
  • HY-U00426
    BF738735
    5 Publications Verification

    		 PI4K Reverse Transcriptase Infection
    BF738735 is a phosphatidylinositol 4-kinase III beta (PI4KIIIβ) inhibitor with an IC50 of 5.7 nM.
    BF738735
  • HY-101019
    Ossirene
    2 Publications Verification

    AS101

    		 Interleukin Related Caspase Inflammation/Immunology Cancer
    Ossirene (AS101), an immunomodulatory tellurium compound, is a potent IL-1β inhibitor . Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene potently inhibits Caspase-1 and is used for the autoimmune diseases and certain malignancies [4].
    Ossirene
  • HY-112613
    UCB9608
    1 Publications Verification

    		 PI4K Inflammation/Immunology
    UCB9608 is a potent, selective and orally active PI4KIIIβ inhibitor, with an IC50 of 11 nM, selective over PI3KC2 α, β, and γ lipid kinases. UCB9608 improves metabolic stability and exhibits excellent pharmacokinetic profile, acts as a potent immunosuppressive agent [1].
    UCB9608
  • HY-19798
    PI4KIIIbeta-IN-9
    5 Publications Verification

    		 PI4K PI3K Cancer
    PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC50 of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC50s of 152 nM and 1046 nM, respectively.
    PI4KIIIbeta-IN-9
  • HY-126144
    GSK-3β inhibitor 1
    4 Publications Verification

    		 GSK-3 Metabolic Disease Cancer
    GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC50 of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats [1].
    GSK-3β inhibitor 1
  • HY-110248
    MI 14

    		PI4K HCV Infection
    MI 14 is a selective PI4KIIIβ inhibitor with IC50s of 54 nM, >100 μM, >100 μM for PI4KIIIβ, PI4KIIIα, PI4KIIα, respectively. MI 14 has antiviral activity against HCV 1b, CVB3, HRVM, HVC 2a [1].
    MI 14
  • HY-106012
    PI4K-IN-1

    		PI4K PI3K Cancer
    PI4K-IN-1 (compound 44) is a potent PI4KIII inhibitor, with pIC50 values of 9.0 and 6.6 for PI4KIIIα and PI4KIIIβ, respectively. PI4K-IN-1 also inhibits PI3Kα/β/γ/δ, with pIC50 values of 4.0/<3.7/5.0/<4.1, respectively [1].
    PI4K-IN-1
  • HY-13335
    PKCβ inhibitor 1
    1 Publications Verification

    		 PKC Apoptosis Cancer
    PKCβ inhibitor 1 is a potent, ATP-competitive, and selective PKCβ inhibitor with IC50s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively. PKCβ inhibitor 1 exhibits selectivity of more than 60-fold in favor of PKCβ2 relative to other PKC isozymes (PKCα, PKCγ, and PKCε) [1] .
    PKCβ inhibitor 1
  • HY-123900
    AZ12799734

    		TGF-β Receptor Cardiovascular Disease
    AZ12799734 is a selective, orally active TGFBR1 kinase inhibitor with an IC50 of 47 nM. AZ12799734 is also a pan BMP and TGFβ inhibitor .
    AZ12799734
  • HY-18748
    BQR-695
    1 Publications Verification

    NVP-BQR695

    		 PI4K Parasite Infection
    BQR-695 is a PI4KIIIβ inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.
    BQR-695
  • HY-148075
    PI4KIIIbeta-IN-11

    		PI4K Infection
    PI4KIIIbeta-IN-11 is an inhibitor of PI4KIIIβ, with a mean pIC50 value of at least 9.1. PI4KIIIβ plays a key role in diseases research of RNA viruses and Plasmodium falciparum [1] .
    PI4KIIIbeta-IN-11
  • HY-P5189A
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA

    		Endogenous Metabolite Cholinesterase (ChE) Others
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels [1].
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA
  • HY-172255
    PI4KIII beta inhibitor 4

    		PI4K Apoptosis Autophagy PI3K Akt Cancer
    PI4KIII beta inhibitor 4 (Compound 16) is a selective PI4KIIIβ inhibitor with an IC50 of 0.005 μM. PI4KIIIβ inhibitor 4 induces tumor cell apoptosis, cell cycle arrest, and autophagy by inhibiting the PI3K/AKT pathway. PI4KIIIβ inhibitor 4 can be used in the study of cancer [1].
    PI4KIII beta inhibitor 4
  • HY-172256
    PI4KIII beta inhibitor 5

    		PI4K Cancer
    PI4KIII beta inhibitor 5 is a PI4KIIIβ inhibitor with an IC50 of 19 nM. PI4KIII beta inhibitor 5 can induce cancer cell apoptosis (Apoptosis), cell cycle arrest at the G2/M phase, and autophagy (Autophagy) by inhibiting the PI3K/AKT pathway. PI4KIII beta inhibitor 5 has also demonstrated significant antitumor activity in the H446 xenograft model of small cell lung cancer. PI4KIII beta inhibitor 5 can be used for research in the field of cancer therapy [1].
    PI4KIII beta inhibitor 5
  • HY-100603A
    (S)-GSK-F1

    		PI3K PI4K Infection
    (S)-GSK-F1 (Compound 28) is an inhibitor for type III phosphatidylinositol 4-kinase α (PI4KIIIα). (S)-GSK-F1 inhibits PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ and PI3Kδ with pIC50 of 8.3, 6.0, 5.6, 5.6, 5.1 and 5.6, respectively. (S)-GSK-F1 exhibits anti-hepatitis C virus (HCV) activity through inhibition of HCV replication. (S)-GSK-F1 exhibits moderate pharmacokinetic characters in rat model [1].
    (S)-GSK-F1
  • HY-118525
    AL-9

    		HCV PI4K Infection
    AL-9 is a inhibitor of PI4KIIIα, with the IC50 of 0.57 μM, that can inhibit HCV replication [1].
    AL-9
  • HY-126144A
    (E/Z)-GSK-3β inhibitor 1

    		GSK-3 Metabolic Disease
    (E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM [1].
    (E/Z)-GSK-3β inhibitor 1
  • HY-161357
    KR-27370

    		PI4K Infection
    KR-27370 (compound 7f) is an antiviral agent and selective PI4KIIIβ/PI4KIIIα inhibitor (IC50: 3.1 nM/15.8 nM), against hRV, Ke Saatchivirus and other enteroviruses have inhibitory activity [1].
    KR-27370
  • HY-118810
    BIO-013077-01

    		TGF-β Receptor Cancer
    BIO-013077-01 is a pyrazole TGF-β inhibitor .
    BIO-013077-01
  • HY-179469
    KR-27452

    		PI4K Enterovirus Infection
    KR-27452 is a selective and orally active PI4KIIIβ inhibitor with an IC50 of 0.026 μM, while showing no activity against PI4KIIIα (IC50 >10 μM) . KR-27452 specifically binds to and inhibits PI4KIIIβ, leading to reduced viral replication in cells. KR-27452 exhibits strong antiviral activity against human rhinovirus (RVs) and Coxsackievirus (COXs). KR-27452 can be used for the research of infection [1].
    KR-27452
  • HY-123536
    AZD2836

    A-831

    		 PI4K HCV Infection
    AZD2836 (A-831) is a 4-aminopyrazolone compound with anti-HCV activity. AZD2836 inhibits the activity of the host cell kinase PI4KIIIα, causing metabolic disorder of the cell membrane component PI4P that is necessary for viral replication. In the HCV subgenomic replicon cell model, the EC50 values of AZD2836 for genotype 1b (Con1 strain) and genotype 1a (Lemon strain) are 270 nM and 550 nM, respectively [1] .
    AZD2836

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: